Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:28:16.610Z.
Calculation as of: 2026-10-06T19:28:16.610Z.
Quote observation: 2026-10-06T19:25:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cf9736c803d76d66c79e1885a68840785ad6b55ce886a17ac328e1a4bc30d25a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$2.07B
EV/EBIT Ratio
N/A
TTM Avg
4584.86x
3Y Avg
4584.86x
5Y Avg
4584.86x
Market Cap
$2.05B
EV/EBIT Ratio
110.86x
TTM Avg
307.23x
3Y Avg
485.43x
5Y Avg
1367.82x
Market Cap
$2.11B
EV/EBIT Ratio
14.29x
TTM Avg
15.46x
3Y Avg
18.22x
5Y Avg
20.56x
Market Cap
$2.12B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.03B
EV/EBIT Ratio
N/A
TTM Avg
41.80x
3Y Avg
41.80x
5Y Avg
41.80x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | $2.08B | N/A | N/A | N/A | N/A |
| Alvotech (ALVO)vs › | $2.08B | 71.60x | 53.16x | 49.42x | 49.42x |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.07B | N/A | 4584.86x | 4584.86x | 4584.86x |
| Viridian Therapeutics, Inc. (VRDN)vs › | $2.05B | N/A | N/A | N/A | N/A |
| Vericel Corporation (VCEL)vs › | $2.05B | 110.86x | 307.23x | 485.43x | 1367.82x |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 14.29x | 15.46x | 18.22x | 20.56x |
| SELLAS Life Sciences Group, Inc. (SLS)vs › | $2.12B | N/A | N/A | N/A | N/A |
| Progyny, Inc. (PGNY)vs › | $2.03B | 17.01x | 21.63x | 33.37x | 79.37x |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.03B | N/A | 41.80x | 41.80x | 41.80x |
| Fortrea Holdings Inc. (FTRE)vs › | $2.01B | 269.29x | 247.10x | 123.52x | 99.39x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
